Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with... Oncol Ther (2016) 4:211–223 DOI 10.1007/s40487-016-0027-x ORIGINAL RESEARCH A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study . . . Ve ´ ronique Die ´ras Thomas Bachelot Mario Campone . . . . Nicolas Isambert Florence Joly Christophe Le Tourneau Philippe Cassier . . . Emmanuelle Bompas Pierre Fumoleau Sabine Noal . . . Christine Orsini Marta Jimenez Diane Charlotte Imbs Etienne Chatelut Received: May 25, 2016 / Published online: August 18, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com were planned. MTD was based on DLT observed ABSTRACT during cycles 1 and 2. Introduction: To determine the feasibility, Results: Thirty-five patients were enrolled. The maximum-tolerated dose (MTD), and MTD was reached at the first DL, (pazopanib dose-limiting toxicities (DLT) of pazopanib in 400 mg daily ? cisplatin 75 mg/m every combination with cisplatin. 21 days). Main DLTs were pulmonary Methods: Patients with advanced malignancies embolism, neutropenia, thrombocytopenia, were included in a 3 ? 3 dose-escalation phase I and elevation of liver enzymes. Overall, most study. Pazopanib administration started 8 days common adverse events were anemia (83%), before the first infusion of cisplatin; http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

Download PDF
13 pages

Loading next page...
 
/lp/springer-journals/a-phase-i-dose-escalation-trial-of-pazopanib-in-combination-with-Oxy2tYLBT6
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0027-x
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:211–223 DOI 10.1007/s40487-016-0027-x ORIGINAL RESEARCH A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study . . . Ve ´ ronique Die ´ras Thomas Bachelot Mario Campone . . . . Nicolas Isambert Florence Joly Christophe Le Tourneau Philippe Cassier . . . Emmanuelle Bompas Pierre Fumoleau Sabine Noal . . . Christine Orsini Marta Jimenez Diane Charlotte Imbs Etienne Chatelut Received: May 25, 2016 / Published online: August 18, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com were planned. MTD was based on DLT observed ABSTRACT during cycles 1 and 2. Introduction: To determine the feasibility, Results: Thirty-five patients were enrolled. The maximum-tolerated dose (MTD), and MTD was reached at the first DL, (pazopanib dose-limiting toxicities (DLT) of pazopanib in 400 mg daily ? cisplatin 75 mg/m every combination with cisplatin. 21 days). Main DLTs were pulmonary Methods: Patients with advanced malignancies embolism, neutropenia, thrombocytopenia, were included in a 3 ? 3 dose-escalation phase I and elevation of liver enzymes. Overall, most study. Pazopanib administration started 8 days common adverse events were anemia (83%), before the first infusion of cisplatin;

Journal

Oncology and Therapy – Springer Journals

Published: Aug 18, 2016

References

  • Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
    Jain, RK
  • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Sandler, A; Gray, R; Perry, MC
  • First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
    Miles, DW; Dieras, V; Cortes, J
  • Improved survival with bevacizumab in advanced cervical cancer
    Tewari, KS; Sill, MW; Long, HJ
  • Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms
    Erber, R; Thurnher, A; Katsen, AD
  • Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
    Bible, KC; Suman, VJ; Molina, JR
  • A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H
    Bible, KC; Suman, VJ; Molina, JR
  • Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
    Ahn, HK; Choi, JY; Kim, KM
  • A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium
    Taylor, SK; Chia, S; Dent, S
  • A phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
    Plummer, R; Madi, A; Jeffels, M
  • Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors
    Infante, JR; Novello, S; Ma, WW
  • An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer
    Scagliotti, GV; Felip, E; Besse, B
  • Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors
    Tan, AR; Dowlati, A; Jones, SF
  • A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors
    Kendra, K; Plummer, R; Salgia, R
  • Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors
    Burris, HA; Dowlati, A; Moss, RA
  • Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
    Tan, AR; Dowlati, A; Stein, MN
  • Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules
    Hamberg, P; Mathijssen, RH; Bruijn, P
  • Phase I study of pazopanib and ixabepilone in patients with solid tumors
    Ganesan, C; Obulareddy, SJ; Fischer, JH
  • Pharmacokinetic interaction between pazopanib and cisplatin regimen
    Imbs, DC; Dieras, V; Bachelot, T
  • Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials
    Funakoshi, T; Latif, A; Galsky, MD
  • Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey
    Paoletti, X; Le, Tourneau C; Verweij, J
  • Phase I trial of pazopanib in patients with advanced cancer
    Hurwitz, HI; Dowlati, A; Saini, S
  • Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms
    Motzer, RJ; Johnson, T; Choueiri, TK
  • Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study
    Hamberg, P; Boers-Sonderen, MJ; Graaf, WT
  • Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group
    Bois, A; Vergote, I; Wimberger, P
  • Aprepitant for erlotinib induced pruritus
    Vincenzi, B; Tonini, G; Santini, D
  • Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
    Heath, EI; Blumenschein, GR; Cohen, RB
  • SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma
    Geldart, T; Chester, J; Casbard, A
  • Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies-results of a phase I dose-escalation study
    Blais, N; Camidge, DR; Jonker, DJ
  • Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer
    Polcher, M; Eckhardt, M; Coch, C
  • A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
    Lee, JK; Capanu, M; O’Reilly, EM
  • Incorporation of pazopanib in maintenance therapy of ovarian cancer
    Bois, A; Floquet, A; Kim, JW
  • Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    Burstein, HJ; Elias, AD; Rugo, HS
  • TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer
    Isakoff, SJ; Mayer, EL; He, L